The abstract is read at the publisher; the summary is JClub's.
Benmelstobart plus anlotinib improved independent review committee–assessed progression-free survival to a median 15.1 months versus 4.2 months with placebo in unresectable stage III NSCLC.
- Why it matters: After chemoradiotherapy for unresectable stage III non-small cell lung cancer, progression remains common, so more effective consolidation strategies are needed.
- What they did: In a multicenter double-blind phase 3 trial in China (2020–2023), patients without progression after chemoradiotherapy were randomized to benmelstobart plus anlotinib, benmelstobart alone, or placebo, with IRC-assessed PFS as the primary endpoint.
- The result: Benmelstobart significantly improved PFS versus placebo (HR 0.49; P < .001), but adding anlotinib did not significantly improve PFS versus benmelstobart alone in pooled analysis (HR 0.82; P = .12) and increased grade 3–5 treatment-related adverse events (48.8% vs 29.4%) and grade 5 events (7.2% vs 1.4%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.